These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 38566336

  • 1. Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium.
    Ashoor IF, Al-Akash S, Kizilbash S, Moudgil A, Puliyanda D, Ranabothu S, Shi Y, Dharnidharka V.
    Pediatr Transplant; 2024 May; 28(3):e14743. PubMed ID: 38566336
    [Abstract] [Full Text] [Related]

  • 2. Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center.
    Dogan B, Sema YA, Bora K, Veysel U, Benan D, Ezgi KT, Gozde AK, Demir D, Ozsan N, Hekimgil M, Zumrut SB, Miray K, Funda C, Sema A.
    J Med Virol; 2024 Jun; 96(6):e29767. PubMed ID: 38932460
    [Abstract] [Full Text] [Related]

  • 3. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.
    Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, Khan F, Taparia M, Jimenez-Zepeda VH, Stewart DA, Daly A, Storek J.
    Cytotherapy; 2018 May; 20(5):706-714. PubMed ID: 29580864
    [Abstract] [Full Text] [Related]

  • 7. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, Merli P, Barzon L, Murer L, Piga S, Ciofi Degli Atti ML, Locatelli F, Dello Strologo L.
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
    Chang YC, Young RR, Mavis AM, Chambers ET, Kirmani S, Kelly MS, Kalu IC, Smith MJ, Lugo DJ.
    PLoS One; 2022 Aug; 17(10):e0269766. PubMed ID: 36256635
    [Abstract] [Full Text] [Related]

  • 9. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F.
    Virol J; 2011 Sep 05; 8():421. PubMed ID: 21892950
    [Abstract] [Full Text] [Related]

  • 10. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
    San-Juan R, Manuel O, Hirsch HH, Fernández-Ruiz M, López-Medrano F, Comoli P, Caillard S, Grossi P, Aguado JM, ESGICH PTLD Survey Study Group,, European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID).
    Clin Microbiol Infect; 2015 Jun 05; 21(6):604.e1-9. PubMed ID: 25686696
    [Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
    Solano C, Mateo EM, Pérez A, Talaya A, Terol MJ, Albert E, Giménez E, Vinuesa V, Piñana JL, Boluda JCH, Navarro D.
    J Clin Virol; 2017 Dec 05; 97():26-32. PubMed ID: 29096390
    [Abstract] [Full Text] [Related]

  • 12. Use of Rituximab for persistent EBV DNAemia, and Its effect on donor-specific antibody development in pediatric renal transplant recipients: A case series.
    Puliyanda DP, Jordan SC, Kim IK, Patel M, Murthy A, Huang E, Zhang X, Reinsmoen N, Kamil ES, Toyoda M.
    Pediatr Transplant; 2021 Dec 05; 25(8):e14113. PubMed ID: 34418254
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
    Tajima T, Martinez OM, Bernstein D, Boyd SD, Gratzinger D, Lum G, Sasaki K, Tan B, Twist CJ, Weinberg K, Armstrong B, Desai DM, Mazariegos GV, Chin C, Fishbein TM, Tekin A, Venick RS, Krams SM, Esquivel CO.
    Pediatr Transplant; 2024 Jun 05; 28(4):e14763. PubMed ID: 38682750
    [Abstract] [Full Text] [Related]

  • 14. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 05; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 15. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.
    Transpl Infect Dis; 2019 Dec 05; 21(6):e13182. PubMed ID: 31556214
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J, Yong MK, Greenwood M, Kong DCM, Chen SCA, Rawlinson W, Slavin M.
    Rev Med Virol; 2020 Jul 05; 30(4):e2108. PubMed ID: 32301566
    [Abstract] [Full Text] [Related]

  • 17. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
    Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N, Touloumenidou T, Zerva P, Kika F, Iskas M, Batsis I, Mallouri D, Yannaki E, Anagnostopoulos A, Sakellari I.
    Int J Mol Sci; 2023 Nov 07; 24(22):. PubMed ID: 38003218
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J, Juamperez J, Mercadal-Hally M, Larrarte King M, Gallego Melcon S, Gros Subias L, Sábado Álvarez C, Soler-Palacin P, Melendo Pérez S, Esperalba J, Navarro Jiménez A, Garrido Pontnou M, Camacho Soriano J, Hidalgo Llompart E, Bilbao Aguirre I, Charco Torra R.
    Pediatr Transplant; 2022 Sep 07; 26(6):e14292. PubMed ID: 35466492
    [Abstract] [Full Text] [Related]

  • 19. Rituximab for posttransplant lymphoproliferative disorder - therapeutic, preemptive, or prophylactic?
    Storek J, Lindsay J.
    Bone Marrow Transplant; 2024 Jan 07; 59(1):6-11. PubMed ID: 38001229
    [Abstract] [Full Text] [Related]

  • 20. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb 07; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.